Zea Biosciences Signs Exclusive License Agreement with the University of Pennsylvania for Hemophilia A, B Oral Tolerance Programs
WALPOLE, Mass., March 28, 2023 /PRNewswire-PRWeb/ -- Zea Biosciences, a Boston-based biopharmaceutical company with a new platform for biologics and vaccine development, has signed an exclusive license agreement with the University of Pennsylvania and the University of Florida. The strategic partnership will aim to rapidly develop and scale potential products for clinical development to address the issue of oral tolerance in Hemophilia A and B patients.
- Strategic partnership accelerates the development of biologic products for addressing oral tolerance in Hemophilia A and B patients.
- WALPOLE, Mass., March 28, 2023 /PRNewswire-PRWeb/ -- Zea Biosciences, a Boston-based biopharmaceutical company with a new platform for biologics and vaccine development, has signed an exclusive license agreement with the University of Pennsylvania and the University of Florida .
- The strategic partnership will aim to rapidly develop and scale potential products for clinical development to address the issue of oral tolerance in Hemophilia A and B patients.
- "We are very excited about this collaboration with the University of Pennsylvania, as it is a beneficial relationship for both of our organizations," said Jim Wilson, founder of Zea Biosciences.